Gemcitabine Ups Survival After Surgery in Pancreatic Cancer

Gemcitabine Ups Survival After Surgery in Pancreatic Cancer

• The main result of this trial is that treatment with adjuvant gemcitabine for 6 months leads to a 24% improvement in overall survival, with a statistically significant absolute 10.3% improvement in the 5-year overall survival rate (20.7% vs 10.4%) and a 4.5% improvement in the 10-year survival rate (12.2% vs 7.7%), compared with observation alone,

Related articles

• Adjuvant gemcitabine improves long-term survival rates of patients with pancreatic cancer
• Chemotherapy Drug Ensures Disease-free Survival Following Surgery for Pancreatic Cancer
• Pancreatic cancer: chemo drug Gemzar improves survival rates
• Abraxane FDA Approved For Treatment In Late-Stage Pancreatic Cancer Treatment